Ziltivekimab for heart attack patients with artery plaque
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a recent heart attack and had a stent placed to open a blocked artery.
- You are 18 years old or older.
- You have at least 2 main heart arteries that can be seen with special imaging after the stent procedure.
- You are not able to become pregnant (women who could become pregnant are excluded).
- You do not have severe kidney or liver disease, active infections, or a history of cancer in the last 5 years (except for certain minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This study tests a new medicine called YMI024 for people with stable coronary artery disease (blockages in heart arteries) and higher than normal levels of inflammation. The drug aims to reduce inflammation and may lower the risk of future heart problems.
This study tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) before a heart procedure to open blocked arteries can help people who are having a heart attack. The medicine may improve outcomes by lowering cholesterol quickly after the event.
This trial tests if meplazumab can help people with chronic coronary syndrome who have stable angina. It focuses on patients with certain fatty deposits around their heart arteries that show up on a special CT scan.
This trial is testing a new way to quickly measure the level of a blood thinner (tirofiban) in the blood of people having a heart attack. It aims to make sure the dose is right and safe for each patient.
This study tests a drug called ziltivekimab to see if it can reduce fatty plaque buildup in heart arteries after a heart attack. It's for people who had a heart attack treated with a stent and have mild blockages in other arteries.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.